T · 4151.T · DRUG MANUFACTURERS - GENERAL
Kyowa Kirin Co., Ltd. (4151.T) intrinsic value and stock valuation
$2,544.00as of 2026-11-21 · Mkt cap 1.3T
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Kyowa Kirin Co., Ltd. DCF and intrinsic value
InvestorsCraft values 4151.T with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from 4151.T’s statements →
Kyowa Kirin Co., Ltd. Graham Number
Graham Number: $2,217.62d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $496.8B | $495.6B | $442.2B | $398.4B | $352.2B |
| Operating income | $102.3B | $91.9B | $95.8B | $82.4B | $61.1B |
| Net income | $67B | $59.9B | $81.2B | $53.6B | $52.3B |
| EPSd | $128.1M | $113.1M | $151M | $99.7M | $97.4M |
| Operating cash flow | $96.6B | $67.9B | $115.6B | $48.7B | $86.5B |
| Capital expenditure | -$-37.72B | -$-26.04B | -$-17.21B | -$-15.56B | -$-6.52B |
| Free cash flow | $58.9B | $41.8B | $98.3B | $33.1B | $80B |
| Total assets | $1.11T | $1.07T | $1.03T | $939.9B | $921.9B |
| Total debt | $26.1B | $21.7B | $19.7B | $22.3B | $16.6B |
| Net debt | -$-192.64B | -$-223.01B | -$-383.39B | -$-316.91B | -$-318.49B |
| Total equity | $893.3B | $850.8B | $836.4B | $762.8B | $737.2B |
| Cash and short-term investments | $218.8B | $244.7B | $403.1B | $339.2B | $335.1B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $496.8B | $495.6B | $442.2B | $398.4B | $352.2B |
| Cost of revenue | $140.5B | $144.3B | $121.6B | $97B | $98.4B |
| Gross profit | $356.4B | $351.2B | $320.6B | $301.4B | $253.9B |
| Research and development expenses | $101.2B | $103.5B | $72.1B | $62.9B | $57.7B |
| Selling, general and administrative expenses | $152.9B | $155.8B | $163.1B | $166.2B | $135.1B |
| Other expenses | $0.00 | $0.00 | -$-10.41B | -$-10.09B | $0.00 |
| Operating expenses | $254.1B | $259.4B | $224.8B | $219B | $192.8B |
| Cost and expenses | $394.6B | $403.7B | $346.4B | $316B | $291.1B |
| Interest income | $2.41B | $1.54B | $702M | $641M | $668M |
| Interest expense | $1.54B | $709M | $190M | $1.09B | $244M |
| Depreciation and amortization | $26.1B | $24.8B | $21.1B | $18.5B | $19.5B |
| Ebitda | $128.4B | $116.6B | $116.9B | $100.9B | $80.6B |
| Operating income | $102.3B | $91.9B | $95.8B | $82.4B | $61.1B |
| Total other income/expenses, net | -$-15.05B | -$-8.41B | $1.4B | -$-14.8B | -$-1.06B |
| Income before tax | $87.2B | $83.5B | $97.2B | $67.6B | $60.1B |
| Income tax expense | $20.2B | $23.6B | $16.1B | $14B | $7.7B |
| Net income | $67B | $59.9B | $81.2B | $53.6B | $52.3B |
| Weighted average shares outstanding | $523.5M | $529.5M | $537.6M | $537.4M | $537.3M |
| Weighted average diluted shares outstanding | $523.5M | $529.6M | $537.6M | $537.6M | $537.5M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $218.8B | $244.7B | $403.1B | $339.2B | $335.1B |
| Net receivables | $181.2B | $157B | $119.1B | $111.7B | $104.3B |
| Inventory | $67.4B | $72.9B | $71.4B | $70.7B | $64.1B |
| Total current assets | $493.3B | $504B | $611.1B | $542.2B | $518.2B |
| Property, plant and equipment, net | $141.2B | $111.5B | $94.5B | $89.1B | $78.7B |
| Goodwill and intangible assets | $384.9B | $346.3B | $203.4B | $200.5B | $212.4B |
| Long-term investments | $25.8B | $36B | $45.7B | $36.5B | $45.2B |
| Total non-current assets | $614.5B | $563.3B | $414.8B | $397.7B | $403.6B |
| Total assets | $1.11T | $1.07T | $1.03T | $939.9B | $921.9B |
| Accounts payable | $125B | $121.1B | $93B | $70.9B | $64.7B |
| Short-term debt | $0.00 | $0.00 | $3.59B | $4.74B | $0.00 |
| Deferred revenue | $0.00 | $0.00 | $4.02B | $0.00 | $0.00 |
| Total current liabilities | $181.1B | $164.7B | $133.2B | $109.8B | $109.1B |
| Long-term debt | $26.1B | $21.7B | $16.1B | $17.5B | $16.6B |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $33.5B | $51.9B | $56.3B | $67.2B | $75.6B |
| Capital lease obligations | $26.1B | $21.7B | $19.7B | $22.3B | $16.6B |
| Total liabilities | $214.5B | $216.6B | $189.5B | $177.1B | $184.7B |
| Common stock | $26.7B | $26.7B | $26.7B | $26.7B | $26.7B |
| Retained earnings | $406.3B | $371.1B | $338.8B | $285.8B | $255.5B |
| Accumulated other comprehensive income (loss) | $38.1B | $31.2B | $9.11B | -$-11.02B | -$-5.91B |
| Total equity | $893.3B | $850.8B | $836.4B | $762.8B | $737.2B |
| Total investments | $25.8B | $36B | $45.7B | $36.5B | $45.2B |
| Total debt | $26.1B | $21.7B | $19.7B | $22.3B | $16.6B |
| Net debt | -$-192.64B | -$-223.01B | -$-383.39B | -$-316.91B | -$-318.49B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $67B | $59.9B | $81.2B | $53.6B | $52.3B |
| Depreciation and amortization | $26.1B | $24.8B | $21.1B | $18.5B | $19.5B |
| Stock-based compensation | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Change in working capital | -$-22.74B | -$-22.18B | -$-2.42B | -$-28.47B | $21.1B |
| Accounts receivable | -$-22.42B | -$-31.53B | -$-2.93B | -$-2.7B | -$-5.9B |
| Inventory | $2.8B | -$-1.65B | -$-3.31B | -$-8.9B | -$-8.28B |
| Accounts payable | -$-5.24B | -$-694M | $4.84B | -$-5.87B | -$-126M |
| Net cash provided by operating activities | $96.6B | $67.9B | $115.6B | $48.7B | $86.5B |
| Investments in property, plant and equipment | -$-83.52B | -$-105.27B | -$-32.85B | -$-28.67B | -$-19.77B |
| Acquisitions, net | $4.14B | -$-42.46B | $5B | $4B | $0.00 |
| Net cash used for investing activities | -$-89.19B | -$-142.39B | -$-20.38B | -$-17.19B | -$-11.36B |
| Common stock issued | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | -$-9M | -$-40.01B | -$-10M | -$-11M | -$-23M |
| Dividends paid | -$-30.88B | -$-30.9B | -$-29.03B | -$-25.26B | -$-24.18B |
| Net cash used for financing activities | -$-36.85B | -$-84.7B | -$-32.54B | -$-29.03B | -$-28.45B |
| Net change in cash | -$-25.91B | -$-158.4B | $63.9B | $4.11B | $48.1B |
| Cash at end of period | $218.8B | $244.7B | $403.1B | $339.2B | $335.1B |
| Operating cash flow | $96.6B | $67.9B | $115.6B | $48.7B | $86.5B |
| Capital expenditure | -$-37.72B | -$-26.04B | -$-17.21B | -$-15.56B | -$-6.52B |
| Free cash flow | $58.9B | $41.8B | $98.3B | $33.1B | $80B |
Line items
Line items
Line items
About Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.
- CEO
- Abdul Hafeez Mullick
- Employees
- 5.67K
- Beta
- 0.10
Included in
Explore
Frequently asked questions
What is the intrinsic value of Kyowa Kirin Co., Ltd. (4151.T)?
InvestorsCraft does not currently publish an intrinsic value for 4151.T. How the IC value is calculated.
Is 4151.T undervalued?
InvestorsCraft does not publish an undervaluation signal for 4151.T at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.